It is also approved for use in combination with an aromatase inhibitor for the treatment of post-menopausal patients with HER2 and hormone receptor co-positive metastatic breast cancer.

• 赫赛汀还被批准联合芳香化酶抑制剂用于HER2和激素受体双阳性的绝经后转移性乳腺癌患者。